Novel insights into adiponectin action in breast cancer: Evidence of its mechanistic effects mediated by ERα expression. (17th February 2020)

• Record Type: Journal Article
• Authors: Andò, Sebastiano; Naimo, Giuseppina Daniela; Gelsomino, Luca; Catalano, Stefania; Mauro, Loredana
• Is Part Of: Obesity reviews. Volume 21:Number 5(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-02-17
• Subjects: adiponectin -- breast cancer -- estrogen receptor alpha -- obesity; Obesity -- Periodicals; 616.398005
• DOI: 10.1111/obr.13004
• Languages: English
• ISSNs: 1467-7881

Abstract

Summary: This review describes the multifaceted effects of adiponectin on breast cancer cell signalling, tumour metabolism, and microenvironment. It is largely documented that low adiponectin levels are associated with an increased risk of breast cancer. However, it needs to be still clarified what are the extents of the decrease of local/intra‐tumoural adiponectin concentrations, which promote breast tumour malignancy. Most of the anti‐proliferative and pro‐apoptotic effects induced by adiponectin have been obtained in breast cancer cells not expressing estrogen receptor alpha (ERα). Here, we will highlight recent findings demonstrating the mechanistic effects through which adiponectin is able to fuel genomic and non‐genomic estrogen signalling, inhibiting LKB1/AMPK/mTOR/S6K pathway and switching energy balance. Therefore, it emerges that the reduced adiponectin levels in patients with obesity work to sustain tumour growth and progression in ERα‐positive breast cancer cells. All this may contribute to remove the misleading paradigm that adiponectin univocally inhibits breast cancer cell growth and progression independently on ERα status. The latter concept, here clearly provided by pre‐clinical studies, may have translational relevance adopting adiponectin as a potential therapeutic tool. Indeed, the interfering role of ERα on adiponectin action addresses how a separate assessment of adiponectin treatment needs to be considered in novel therapeutic strategies for ERα‐positive and ERα‐negative breast cancer.